Novel SGLT Inhibitor (SGL5094) Improves Postprandial Hyperglycemia Through the Suppression of SGLT1-Mediated Glucose Transport Across the Small Intestine.
- Published in:
- Diabetes, 2007, v. 56, p. A136
- By:
- Publication type:
- Article
Works by Fukasawa, Yoshiki
Results: 4
1
2
Novel SGLT Inhibitors (SGL5083 and SGL5085), Acting on Both Suppressing Intestinal Glucose Absorption and Increasing Urinary Glucose Excretion, Improve Postprandial Hyperglycemia in Diabetic Model Rats.
- Published in:
- Diabetes, 2007, v. 56, p. A136
- By:
- Publication type:
- Article
3
In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
- Published in:
- Xenobiotica, 2017, v. 47, n. 4, p. 314, doi. 10.1080/00498254.2016.1193913
- By:
- Publication type:
- Article
4
Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
- Published in:
- Xenobiotica, 2015, v. 45, n. 12, p. 1105, doi. 10.3109/00498254.2015.1042947
- By:
- Publication type:
- Article